Kairos Pharma, Ltd. (KAPA)
NYSEAMERICAN: KAPA · Real-Time Price · USD
0.5521
-0.0459 (-7.68%)
May 29, 2025, 4:00 PM - Market closed

Kairos Pharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-3.54-2.6-1.81-1.05-2.15
Depreciation & Amortization
0.160.160.160.160.1
Other Amortization
0.150.150.060.410.14
Stock-Based Compensation
0.270.22--0.3
Other Operating Activities
0.10.10.91--
Change in Accounts Payable
-0.090.40.770.131.19
Change in Other Net Operating Assets
-1.76-2.39-0.01--
Operating Cash Flow
-4.71-3.960.08-0.35-0.41
Cash Acquisitions
-----0.11
Investing Cash Flow
-----0.11
Short-Term Debt Issued
-0.14---
Long-Term Debt Issued
---0.930.35
Total Debt Issued
0.140.14-0.930.35
Short-Term Debt Repaid
--0.14--0.04-0.02
Total Debt Repaid
-0.14-0.14--0.04-0.02
Net Debt Issued (Repaid)
---0.890.33
Issuance of Common Stock
5.525.52--0.25
Other Financing Activities
2.76-0.39-0.43-0.17-
Financing Cash Flow
8.285.13-0.430.720.58
Net Cash Flow
3.581.18-0.340.360.06
Cash Interest Paid
00---
Levered Free Cash Flow
-5.9-5.350.760.01-
Unlevered Free Cash Flow
-5.96-5.380.77-0.12-
Change in Net Working Capital
4.324.3-0.76-0.08-
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q